Inventiva

IVA

Market cap $804M

Daix (France), New York City, (New York, United States), November 21, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today reported its cash position as of September 30, 2025 and its revenues for the first nine months of 2025.

Daix (France), New York City (New York, United States), November 17, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced that the underwriters of the previously announced public offering in the United States (the "Offering") of 38,961,038 American Depositary Shares ("ADSs"), each representing one ordinary share of the Company with a nominal value of €0.01, have exercised in full their option (the "Underwriters' Option") to purchase 5,844,155 additional ADSs (the "Additional ADSs"). The additional ADSs are expected to be delivered on November 18, 2025.

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.

Daix (France), New York City (New York, United States), November 13, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), announced the trading resumption of its ordinary shares on the regulated market of Euronext in Paris as from 4:30 p.m. (CET).

Daix (France), New York City (New York, United States), November 13, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced the pricing of its previously announced underwritten public offering, in the United States only, of 38,961,038 new American Depositary Shares ("ADSs"), each representing one new ordinary share of the Company with a nominal value of €0.01, at an offering price of $3.85 per ADS (the "Offering"). Settlement and delivery of the Offering is expected on November 17, 2025, subject to the satisfaction of customary closing conditions.

Daix (France), New York City (New York, United States), November 13, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), announced today that trading of its ordinary shares on the regulated market of Euronext Paris ("Euronext Paris") will be temporarily halted, at the Company's request, from the opening of the market at 9:00 a.m. (CET). This trading halt takes place in the context of the previously announced public offering by the Company in the United States only of new American Depositary Shares (the "ADSs"), each representing one new ordinary share of the Company with a nominal value of €0.01 (the "Offering"), in order to allow for the confirmation of allocations to investors and the announcement of the pricing of the Offering.

Daix (France), New York City (New York, United States), November 12, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced that it plans to offer and sell approximatively $125 million (representing approximately €108 million) of new American Depositary Shares ("ADSs") each representing one new ordinary share of the Company with a nominal value of €0.01, in an underwritten public offering in the United States only (the "Offering"). The Company's ADSs are listed on the Nasdaq Global Market under the ticker symbol "IVA" and the Company's ordinary shares are listed on the regulated market of Euronext in Paris ("Euronext") under the symbol "IVA". All securities to be sold in the Offering will be offered solely by the Company.

Daix (France), New York City (New York, United States), October 14, 2025 – Inventiva (Euronext Paris and Nasdaq : IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) has filed today a shelf registration statement on Form F-3 (the “Registration Statement”) with the Securities and Exchange Commission (“SEC”). The Registration Statement includes a base prospectus and a sales agreement prospectus for a new At-The-Market (“ATM”) program, and allows the Company to issue and sell, from time to time, "at-the-market", including to unsolicited investors who have expressed an interest, ordinary shares in the form of American Depositary Shares (“ADS”). Each ADS represents one ordinary share of Inventiva, for aggregate gross sales proceeds of up to $100 million (subject to a regulatory limit of 30% dilution over a rolling period of 12 months and within the limits of investors' requests expressed in the context of the program), pursuant to the terms of a new sales agreement entered into with Piper Sandler & Co. (“Piper Sandler”), acting as sales agent.

Inventiva S.A. (NASDAQ:IVA ) Analyst/Investor Day October 8, 2025 11:30 AM EDT Company Participants Mark Pruzanski Andrew Obenshain - CEO & Director Jason Campagna - President of Research and Development & Chief Medical Officer Martine Zimmermann - Executive VP of Regulatory Affairs & Quality Assurance Conference Call Participants William Alazawi Arun Sanyal Nezam H.

Daix (France), New York City (New York, United States), October 7, 2025 -  Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced four abstracts presentations at the upcoming Annual American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025 being held November 7 to 11, 2025 in Washington, DC.